Staska Pharmaceuticals, Inc., Bennet, NE
Is Staska Pharmaceuticals, Inc. an FDA-registered 503B outsourcing facility?
Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Staska Pharmaceuticals, Inc. in Bennet, NE, first registered Dec 3, 2020 and most recently registered Dec 12, 2025. FDA lists its last inspection as Feb 20, 2026, with a Form FDA 483 issued; FDA lists the action on that inspection as “Response Letter Issued 7/23/2026”.
FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.
- Location on FDA’s list
- Bennet, NE
- Initial registration
- Dec 3, 2020
- Most recent registration
- Dec 12, 2025
- Last inspection
- Feb 20, 2026
- Form 483 issued at last inspection
- Yes
- Recall after last inspection
- No
- Action on last inspection
- Response Letter Issued 7/23/2026
- Intends to compound sterile drugs from bulk substances
- Yes
FDA inspections and actions on record
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this facility as Staska Pharmaceuticals, Inc., Bennet, NE, a 503B facility, with 4 listed actions, including 2 Form 483s and 1 warning letter (2024 to 2026).
| Document | |||
|---|---|---|---|
| Feb 20, 2026 | Form 483 | 483 Issued 02/20/2026 | fda.gov |
| May 5, 2025 | Warning letter | Warning Letter (05/05/2025) | fda.gov |
| Sep 26, 2024 | Amended Form 483 | Amended 483 Issued 09/26/2024 | FDA copy (archived) |
| No date given | Recall notice | Firm Press Release: Staska Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Ascorbic Acid Solution for Injection (Preservative Free, Non-Corn) 500mg/mL Due to the Presence of Glass Particles | FDA | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.
Matched to the 503B list by city, state and the exact legal name with the same legal ending. Check the heading above against the facility you are looking for.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Staska Pharmaceuticals, Inc., Bennet, NE (FEI number 3017473850), matched to this page by exact name, city and state. It lists 2 inspections: 2 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Feb 20, 2026 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3017473850 | 1304594 |
| Sep 18, 2024 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3017473850 | 1251377 |
Form 483s FDA has published for this site
- Feb 20, 2026: Form 483 to Staska Pharmaceuticals, Inc., published May 8, 2026. fda.gov
- Sep 18, 2024: Form 483 to Staska Pharmaceuticals, Inc., published Nov 5, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 12 numbered observations in all, across 2 inspections ending Sep 26, 2024 to Feb 20, 2026. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Feb 9, 2026 to Feb 20, 2026: 3 observations
- Firm on the cover
- Staska Pharmaceuticals, Inc., 742 Evergreen Dr, Bennet, NE 68317-2365 TYPE ESTABLISHMENT lNSPECTEO Outsourcing Facility
- FEI number
- 3017473850
- FDA district office on the cover
- 8050 Marshall Drive, Suite 205 Lenexa, KS 66214
- Matched to this page by
- FEI number on the cover; linked from actions page, 503B list, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
Specifically,
Your procedures do not require investigation when Acceptable Quality Limit (AQL) sampling fails after 100% visual inspection.
On July 10, 2025, during visual inspection of Ascorbic Acid Preservative Free Injection batch SP2500050, (batch size: <Redacted B4> units), your initial 100% visual inspection rejected 80 critical, 49 major, and 12 minor defects. Subsequent AQL sampling identified 5 major defects, exceeding your acceptance criterion of <Redacted B4> major defects, and the AQL failed.
Your Quality Unit approved proceeding to <Redacted B4> visual inspection without initiating an investigation to determine why the initial 100% visual inspection failed to detect the 5 major defects found during AQL sampling, without documenting the rationale for this decision, and without evaluating whether other batches may be similarly affected. After <Redacted B4> visual inspection and tightened AQL sampling (which passed), the batch was released. ...
Observation 2
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, standards, sampling plans and test procedures designed to assure that components, in-process materials and drug products conform to appropriate standards of identity, strength, quality and purity.
Specifically,
Your firm lacks adequate controls to ensure the integrity and reliability of analytical data generated by High-Performance Liquid Chromatography (HPLC) systems used for release testing of sterile drug products.
A. Your firm does not have a written procedure requiring review of electronic raw data, audit trails, and system-generated records from HPLC analyses prior to batch release. Your Quality Control (QC) pharmacist reviews only printed reports and manually verifies calculations, but does not review: Your firm's current practice of reviewing only printed summaries and recalculating results does not fulfill the Quality Unit's responsibility to ensure the reliability of analytical data used for batch disposition decisions. ...
Observation 3
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specific ally,
A. Non-Viable Particle Monitoring Probe Orientation On February 12, 2026, during the production of Glutathione (Preserved), Batch SP26012, the orientation of the non-viable particle counter probe was not directed into the flow of air in the monitored location. The probe was positioned <Redacted B4> rather than inline with the <Redacted B4> laminar airflow, preventing representative sampling of the ISO 5 environment where aseptic manipulations occur. Your firm cannot demonstrate that the orientation and placement of the probe provides a meaningful sample of the critical aseptic processing area.
B. Environmental Monitoring Equipment Obstructing First-Pass Air Your firm's procedures for environmental monitoring during production operations do not ensure that monitoring equipment is positioned to avoid compromising unidirectional airflow in the ISO 5 critical zone. ...
Inspection dated Sep 26, 2024 by FDA (dates on the form not read): 9 observations
- Firm on the cover
- Staska Pharmaceuticals Inc., 742 Evergreen Dr., Bennet, NE 6831 7
- FEI number
- 3017473850
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 8050 Marshall Dr., Suite 205 Lenexa, KS 66214
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
There is a failure to thoroughly review any unexplained discrepancy and the failure ofa batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Specifically,
During your firm's visual inspection of Buffered Lidocaine HCl USP 2% 20mg/mL, 50mL Vials for injection Lot <Redacted B4> MFG 08/30/2022, <Redacted B4> vials were rejected due to defects including particles, package defects, sealing defects and abnormal fill volume. Deviation DR/PD/22/09/004 determined the root cause for the defects was contamination and damage incurred during transportation . However, the investigation wasn't expanded to determine if other lots using Lot <Redacted B4> were affected. CAPAs included <Redacted B4> vials to prevent rattling and post-cleaning inspections by the vial manufacturer. The batch was reJected ut no CAPA's were implemented by your firm, and no effectiveness check was conducted. A second deviation occuned on July 19, 2024.
During your firm's visual inspection of Ascorbic Acid 500mg/mL 50mL Vials for sterile injection Lot <Redacted B4> BUD 12/31/2024, you initially identified <Redacted B4> vials containing glass particles. ...
Observation 2
Your firm failed to establish acceptance criteria for the sampling and testing conducted by the quality control unit that are adequate to assure that batches of drug products meet each appropriate specification and appropriate statistical quality control criteria as a condition for their approval and release.
Specifically, In regards to your 100% visual inspection of finished product vials and syringes: Your firm has not implemented a clear· classification scheme for defects, including critical, major, and minor categories nor have you established rejection rates to identify atypical lots. Furthermore, there is no SOP for this process.
Observation 3
Employees engaged in the manufacture and processing of a drug product lack the training required to perform their assigned functions.
Specifically,
A. Your firm has not implemented a clear classification scheme for defects, including critical, major, and minor categories. in addition, there is an absence of established, documented defect characterizations that detail defect size ranges, specific defect locations on containers, and where feasible, photographs of the defects to ensure consistency in defect identification during qualification visual inspections.
B. Your firm has not incorporated defect types routinely encountered during production into the training program. The absence of naturally occuring defects or production rejects in inspector training can limit an inspector's ability to detect actual production-related defects effectively during routine inspections.
C. Your firm has not established a limit for false rejection of acceptable vials during a visual inspection qualification.
D. There is no requirement to conduct a 360-degree visual inspection of each unit. ...
Observation 4
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically, According to SOP MC0l 0, Environmental Monitoring, Rev 06, microbial contamination recovery limits for the elbows or gowning elements of operators are set at Alert NA and Action <Redacted B4>, while the limit for hands or gloves entering the Grade A areas is Action <Redacted B4>. However, when operators conduct interventions in which they open the <Redacted B4> door, both their elbows and hands/gloves enter the ISO 5 area.
SEE Lisa Flores, Lisa L.
Observation 5
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
Specifically,
A . Your firm has not conducted a cleaning validation on product contact equipment including stainless steel mixing pots and mixing impellers to assure your cleaning process removes microbial content or chemical residues on the equipment used in your aseptic operations, <Redacted B4> stainless steel pots were used in batches including but not limited to:
• Methylcobalamin 1 mg/mL 30 mL Preserved Lot <Redacted B4> • Methylcobalamin 5 mg/mL 30 mL Preserved Lot <Redacted B4> • Buffered Lidocaine HCL 1 % (10 mg/mL) Syringes Lot <Redacted B4> • Buffered Lidocaine HCL 1% (10 mg/mL) Syringes Lot <Redacted B4> 7
B. The wet contact times specified in SOP PD016 Cleaning, Disinfection of ISO 5, ISO 7, ISO 8 Areas and Equipment, Rev 5 for cleaners and disinfectants are not consistently being met. During cleaning and disinfection of Room D (ISO 8) on 09/09/2024 Room (ISO 7) on 09/09/2024 and left laminai· flow ~ 09/09/2024, the established <Redacted B4> wet contact time for <Redacted B4> was not met.
Observation 6
Your firm failed to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
Specifically,
A. Your firm has not performed Process Validation (PV) for finished products. You have considered performance of stability studies suitable to satisfy PV requirements. There are no documented / established written PV protocols or reports. From 2021 until the beginning of this inspection, the firm has made <Redacted B4> batches of products including but not limited to:
Product
Batches
Ascorbic Acid 500 mg/ ml 10 ml Syringes
<Redacted B4> Ascorbic Acid 500 mg/ml 50 mlvial
Ascorbic Acid 500 mg/ ml 50 ml vial Preserved
B Complex
Buffered Lidocaine HCl 1% (10mg/ ml) 10 ml syringe
Buffered lidocaine HCl 2% (20 mg/ ml ) 50 ml
Buffered Lidocaine HCl 2% (20 mg/ m l ) Syringes
Glutathione injection (200 mg/ ml)
Glutathione injection (200 mg/ ml) 30 ml Preserved
Methyl Cobalamin 5 mg/ ml 30 ml preserved
Methylcobalamin 1 mg/ ml Preserved 30 mlvial
Methylcobalamin 25 mg/ ml Preserved
Date: 2024.09.26 10:31 :59 -05'00' THIS PAGE ...
Observation 7
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established or followed.
Specifically,
A. Your aseptic personnel practices and interventions are not scientifically justified or documented.
1. Co rrective and inherent interventions are not documented in your batch record.
2. You do not document the amount of time each operator participates in or the activities they perform as part of the media fill for the <Redacted B4> fill line.
3. I nterventions performed during media fills do not reflect routine production.
B. Media fills do not document:
1. Aseptic assembly of equipment ( e.g., at start-up, during processing)
2. Time personnel participate and their activities
Lisa
4. Raw data results of all media vials incubated (results for unknown number of vials or vials associated with interventions only)
C. Growth promotion is not conducted on every lot of <Redacted B4> l received and data loggers are not used to document the conditions of shipping. SOP MC015, Growth Promotion Test of Microbiological Media Effective 1/13/2022 does not require growth promotion to be performed on each batch of purchased <Redacted B4> received. ...
Observation 8
The containers of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(B). Specifically, your containers do not include the following information:
a. Information to facilitate adverse event reporting: www.fda.gov/medwatch and 1-800-FDA-1088;
www.fda.gov/medwatch and 1-800-FDA- 1088;
Examples of your container labels that do not contain this information: Ascorbic Acid Inj. Solution (Preserved, Non-com) 25,000mg/50mL (500mg/mL) • <Redacted B4> Solution • Glutatholone Inj. Solution (Preservative free) 2,000mg/l0mL (200mg/mL) • Lidocaine 2% Buffered Inj . Solution (PF) 1000mg/50mL (20mg/mL)
b. Directions for use, including, as appropriate, dosage and administration.
Examples of your container labels that do not contain this information include: • Ascorbic Acid Inj. Solution (Preserved, Non-com) 25,000mg/50mL (500mg/mL) • Lidocaine 2% Buffered Inj . Solution (PF) 1000mg/50mL (20mg/mL)
Observation 9
Bulk drug substances used by your outsourcing facility to compound drug products are not manufactured by an establishment that is registered under section 510 as required by section 503B(a)(2)(C).
Specifically, The bulk drug substance <Redacted B4> is manufactured by, <Redacted B4>, an establishment that is no longer registered under section 510 as required by section 503B(a)(2)(C).
"Upon completion of any such inspection of a factory, warehouse, consulting laboratory, or other establishment, and prior to leaving the premises, the officer or employee making the inspection shall give to the owner, operator, or agent in charge a report in writing setting forth any conditions or practices observed by him which, in his judgment, indicate that any food, drug, device, or cosmetic in such establishment (1) consists in whole or in part of any filthy, putrid, or decomposed substance, or (2) has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health. A copy of such report shall be sent promptly to the Secretary."
GLP-1 records in this index
No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (Staska Pharmaceuticals, Inc.). That is not a finding beyond this index’s search.
The Staska Pharmaceuticals, Inc. pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA Registered Outsourcing Facilities (503B)
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.